Michelle Habrusiev, PMHNP-BC
Psychiatric/Mental Health · Sunnyvale
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Has dropped Medicare — you would pay privately
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Michelle Habrusiev’s office at (408) 400-3967 to ask if they take your plan before you enroll.
Medicaid work
$470 in 2023
Medicaid paid $470 for 31 billed services this clinician did in 2023, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Psychiatric diagnostic evaluation with medical services | 17 | $310 |
| SBSQ NURSING FACILITY CARE MOD MDM 30 MINUTES | 14 | $160 |
| 2023 | 31 | 2 | 17 | $470 |
Drugs they prescribed that Part D paid
$39,803
Pharmacies billed $39,803 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 260) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
230 generic and 30 brand-name prescriptions · $39,803 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vraylar | 11 | $15,631 | $1,421 |
| Mirtazapine | 20 | $369 | $18 |
| Dextroamphetamine-Amphet Er | 12 | $173 | $14 |
| Gabapentin | 11 | $169 | $15 |
| Sertraline | 19 | $164 | $9 |
See all 10 drugs
| Vraylar | 11 | $15,631 | $1,421 |
| Mirtazapine | 20 | $369 | $18 |
| Dextroamphetamine-Amphet Er | 12 | $173 | $14 |
| Gabapentin | 11 | $169 | $15 |
| Sertraline | 19 | $164 | $9 |
| Duloxetine | 13 | $158 | $12 |
| Divalproex | 11 | $74 | $7 |
| Alprazolam | 17 | $70 | $4 |
| Trazodone | 22 | $70 | $3 |
| Lorazepam | 13 | $29 | $2 |
Year by year
| 2024 | 260 | 28 | 0% (0) | 12% | $39,803 |
| 2023 | 13 | None | 0% (0) | 0% | $522 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Money from drug and device companies
$89 in 2025
| 2025 | 3 | 4 | None | $89 |
| 2024 | 10 | 24 | None | $592 |
| 2023 | 9 | 17 | None | $392 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Lundbeck | Rexulti | $58 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $17 | 1 payment
|
| Tris Pharma | Dyanavel Xr | $14 | 1 payment
|
See all 4 published payments
| Lundbeck | Meals · 2025-04-12 | Rexulti | $23 |
| Lundbeck | Meals · 2025-03-22 | Rexulti | $35 |
| Tris Pharma | Meals · 2025-03-08 | Dyanavel Xr | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-03-06 | Cobenfy | $17 |
See earlier years (2024, 2023)
2024: $592
| Abbvie | Vraylar | $274 | 10 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $81 | 3 payments
|
| Janssen Pharmaceuticals | Spravato | $53 | 2 payments
|
| Alkermes | Aristada | $48 | 2 payments
|
| Otsuka America Pharmaceutical | Rexulti | $37 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $30 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $20 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $19 | 1 payment
|
| Lundbeck | Rexulti | $17 | 1 payment
|
| Axsome Therapeutics | Auvelity | $14 | 1 payment
|
2023: $392
| Iti | Caplyta | $86 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $76 | 4 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $69 | 3 payments
|
| Abbvie | Vraylar | $58 | 2 payments
|
| Alkermes | Aristada | $28 | 1 payment
|
| Janssen Pharmaceuticals | Spravato | $23 | 1 payment
|
| Vanda Pharmaceuticals | Hetlioz | $22 | 1 payment
|
| Lundbeck | Rexulti | $15 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Trintellix | $14 | 1 payment
|
Professional record
- NPI
- 1114560182
- Licence
- CA 95021862, NY 404183, NY 712240
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X); Federal specialty code 163W00000X (163W00000X)
- Mailing address
- 830 Stewart Dr Ste 271, Sunnyvale, CA, 94085
- NPI first listed
- 2019-10-23
- NPI last updated
- 2025-07-27
- NPI record certified
- 2025-07-27
This is when the NPI record was last certified, not a medical board exam.